YOU ARE HERE: LAT HomeCollectionsAmyloid


April 13, 2000
Researchers at the Oklahoma Medical Research Foundation say they have identified a highly effective inhibitor of the enzyme that plays a key role in the onset of Alzheimer's disease. Memapsin 2, also known as beta-secretase, cleaves a protein called amyloid precursor protein, producing protein fragments that damage brain cells. The team reported in Wednesday's Journal of the American Chemical Society that the new inhibitor blocks this process in the test tube. It has not been tested in humans.
December 26, 2013 | By Geoffrey Mohan
Elderly people who have both mild cognitive impairment and a history of serious concussion showed higher amounts of the protein deposits associated with Alzheimer's disease , according to a new study. The results, published Thursday in the journal Neurology, suggest a potential link between a history of head trauma and later cognitive decline. Researchers at the Mayo Clinic in Rochester, Minn., enlisted 589 elderly residents of surrounding Olmsted County, beginning in 2004, and administered a battery of cognitive and memory tests, along with brain scans that reveal both structure and metabolic function.
An important clue to the cause of memory loss associated with Alzheimer's disease has been discovered by researchers at City of Hope in Duarte. Biochemist Eugene Roberts and his City of Hope colleagues report today in the prestigious Proceedings of the National Academy of Sciences that injections of fragments of a brain protein called beta-amyloid into the brains of mice cause the animals to forget tasks they have just learned.
December 3, 2010 | By Shari Roan, Los Angeles Times
Disease-modifying treatments for Alzheimer's disease have proved elusive. However, a study in mice published this week suggests that a treatment strategy relying on gene therapy may be worth pursuing. Researchers at the Gladstone Institute of Neurological Disease in San Francisco found that mice and humans with Alzheimer's disease have unusually low levels of an enzyme called EphB2 in the parts of the brain that control memory. EphB2 plays an important role in fostering communication between brain cells.
December 9, 1991 | From Times Staff and Wire Reports
British scientists said last week that they had discovered a causal link between severe head injuries and Alzheimer's disease, a terminal brain disorder that afflicts an estimated 4 million elderly people in the United States. "It has been argued for a long time that Alzheimer's has several different causes. Our data is the first direct evidence that head injury may be one significant causative factor," said Dr. Gareth Roberts of London's St. Mary's Hospital Medical School.
January 22, 2007 | From Times wire reports
Scientists have identified a gene that increases the risk for late-onset Alzheimer's and provides another clue into the complex mind-robbing disease. The gene -- SORL1 -- stands out because it's been tested in four ethnic groups and a form of it seems to confer a risk in all of them -- including North Europeans, Caribbean Latinos, African Americans and Israeli Arabs.
July 8, 1999
Vaccination with a protein that plays a key role in Alzheimer's disease can halt progression of an Alzheimer's-like disorder in mice and may even reverse some of the symptoms, according to a report in today's Nature. The protein, called AN-1792, is a modified form of beta-amyloid peptide, one of the proteins found in the plaques and tangles in the brain characteristic of Alzheimer's disease.
Scientists at Amgen have isolated an elusive brain chemical believed to play a crucial role in the development of Alzheimer's disease. Reporting their findings in today's edition of Science, the researchers hope the discovery will lead to targeted treatments that can halt the advance of this mind-devouring disease that afflicts an estimated 4 million Americans.
March 25, 2002 | From Times Staff and Wire Reports
A blood test may be able to identify Alzheimer's disease long before there are symptoms of the brain-destroying disorder, allowing early treatment, according to researchers from Washington University School of Medicine in St. Louis. The researchers reported in the March 22 Science that injecting an antibody into mice causes a sudden flood in the bloodstream of a protein that forms neuron-destroying plaques in the brain.
September 8, 1992 | JACK SEARLES
BioSource Industries Inc. of Camarillo has obtained worldwide marketing rights to a test kit for the measurement of Serum Amyloid A, a reagent used in diagnosing such diseases as rheumatoid arthritis as well as secondary infections associated with cystic fibrosis and AIDS. The kit gives BioSource "an excellent opportunity to market a unique test for what we believe could become a substantial market," said James Chamberlain, BioSource's chief executive officer.
Los Angeles Times Articles